Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice

Michael Doubek, Jiří Mayer, Petra Obrtlíková, Lukáš Smolej, Eduard Cmunt, Jiří Schwarz, Martin Brejcha, Petr Kozmon, Šárka Pospíšilová, Yvona Brychtová, Zdeněk Pospíšil, Marek Trněný

. 2011 ; 87 (2) : 130-137.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027572

Grantová podpora
NS10439 MZ0 CEP - Centrální evidence projektů
NS9858 MZ0 CEP - Centrální evidence projektů
NT11218 MZ0 CEP - Centrální evidence projektů

OBJECTIVES: The impact of modern prognostic markers on clinical course of chronic lymphocytic leukaemia (CLL) in everyday practice has been not yet well defined, especially in large series of patients. Therefore, the goal of this study was to assess the influence of conventional as well as modern prognostic factors on overall survival (OS) and time to therapy (TTT) of patients with CLL. METHODS: We retrospectively analysed data of all patients consecutively entered into the databases of five large academic centres in the Czech Republic. The total of 1300 patients was included in the analysis. RESULTS AND CONCLUSION: Through the use of uniparametric analysis, it was determined that gender, clinical stage Rai II-IV, unmutated IgVH status, deletion 17p (for both 5% and 20% cut-off), deletion 11q, ZAP-70 positivity and high expression of CD38 had significant negative influence on OS. TTT was significantly influenced by gender, Rai stage, IgVH status, deletion 11q, deletion 17p, deletion 13q and CD38 expression. Multiparametric analysis revealed that OS was significantly influenced by gender, age, IgVH status and deletion 17p. If only patients who died of CLL were included, gender, age, Rai stage, IgVH status and deletion 17p had significant influence on OS. Based on our results, the examination of biological prognostic markers can give an insight into the possible disease evolution in daily clinical practice. Biological prognostic markers are, however, not ready (maybe except deletion 17p in younger patients) to be used for guidance of therapy at least outside of clinical trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027572
003      
CZ-PrNML
005      
20191007110106.0
007      
ta
008      
120817s2011 enk f 000 0#eng||
009      
AR
024    7_
$a 10.1111/j.1600-0609.2011.01639.x $2 doi
035    __
$a (PubMed)21535162
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Doubek, Michael, $u Department of Internal Medicine-Hematology/Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno. mdoubek@fnbrno.cz $d 1972- $7 mzk2004217554
245    10
$a Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice / $c Michael Doubek, Jiří Mayer, Petra Obrtlíková, Lukáš Smolej, Eduard Cmunt, Jiří Schwarz, Martin Brejcha, Petr Kozmon, Šárka Pospíšilová, Yvona Brychtová, Zdeněk Pospíšil, Marek Trněný
520    9_
$a OBJECTIVES: The impact of modern prognostic markers on clinical course of chronic lymphocytic leukaemia (CLL) in everyday practice has been not yet well defined, especially in large series of patients. Therefore, the goal of this study was to assess the influence of conventional as well as modern prognostic factors on overall survival (OS) and time to therapy (TTT) of patients with CLL. METHODS: We retrospectively analysed data of all patients consecutively entered into the databases of five large academic centres in the Czech Republic. The total of 1300 patients was included in the analysis. RESULTS AND CONCLUSION: Through the use of uniparametric analysis, it was determined that gender, clinical stage Rai II-IV, unmutated IgVH status, deletion 17p (for both 5% and 20% cut-off), deletion 11q, ZAP-70 positivity and high expression of CD38 had significant negative influence on OS. TTT was significantly influenced by gender, Rai stage, IgVH status, deletion 11q, deletion 17p, deletion 13q and CD38 expression. Multiparametric analysis revealed that OS was significantly influenced by gender, age, IgVH status and deletion 17p. If only patients who died of CLL were included, gender, age, Rai stage, IgVH status and deletion 17p had significant influence on OS. Based on our results, the examination of biological prognostic markers can give an insight into the possible disease evolution in daily clinical practice. Biological prognostic markers are, however, not ready (maybe except deletion 17p in younger patients) to be used for guidance of therapy at least outside of clinical trials.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antigeny CD38 $x krev $7 D051997
650    _2
$a chromozomální delece $7 D002872
650    _2
$a lidské chromozomy, pár 11 $x genetika $7 D002880
650    _2
$a lidské chromozomy, pár 17 $x genetika $7 D002886
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a geny pro těžké řetězce imunoglobulinů $7 D050438
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x etiologie $x genetika $x imunologie $x patologie $7 D015451
650    _2
$a difúzní velkobuněčný B-lymfom $x etiologie $7 D016403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a membránové glykoproteiny $x krev $7 D008562
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a analýza přežití $7 D016019
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a protein-tyrosinkináza ZAP-70 $x krev $7 D051746
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mayer, Jiří, $u Department of Internal Medicine-Hematology/Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno $d 1960- $7 nlk20000083651
700    1_
$a Obrtlíková, Petra $u 1st Department of Internal Medicine, General Faculty Hospital, Prague $7 xx0093684
700    1_
$a Smolej, Lukáš $u 2nd Department of Medicine – Department of Hematology, Charles University Hospital and Faculty of Medicine, Hradec Králové $7 xx0101489
700    1_
$a Cmunt, Eduard, $u 1st Department of Internal Medicine, General Faculty Hospital, Prague $d 1952- $7 xx0106898
700    1_
$a Schwarz, Jiří, $u Institute of Hematology and Blood Transfusion, Prague $d 1957- $7 xx0052837
700    1_
$a Brejcha, Martin $u Oncology Center, Nový Jičín $7 xx0105595
700    1_
$a Kozmon, Petr $u Department of Internal Medicine-Hematology/Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0126067
700    1_
$a Pospíšilová, Šárka, $u Department of Internal Medicine-Hematology/Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno $d 1969- $7 xx0101843
700    1_
$a Brychtová, Yvona $u Department of Internal Medicine-Hematology/Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0105542
700    1_
$a Pospíšil, Zdeněk, $u Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic $d 1960- $7 xx0000203
700    1_
$a Trněný, Marek, $u 1st Department of Internal Medicine, General Faculty Hospital, Prague; Institute of Hematology and Blood Transfusion, Prague $d 1960- $7 nlk20000083659
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 87, č. 2 (2011), s. 130-137
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21535162 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20191007110521 $b ABA008
999    __
$a ok $b bmc $g 949614 $s 784918
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 87 $c 2 $d 130-137 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
GRA    __
$a NS10439 $p MZ0
GRA    __
$a NS9858 $p MZ0
GRA    __
$a NT11218 $p MZ0
LZP    __
$a Pubmed-20120817/11/03
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace